Sponsor

Ipsen

Clinical research sponsor

Published trials56

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

56 shown

A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in ItalyNCT05759273 · lead sponsor · 2023-04-24

COMPLETED

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the ProstateNCT05590793 · lead sponsor · 2022-11-17

COMPLETED

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the ProstateNCT05458856 · lead sponsor · 2022-08-30

COMPLETED

Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer TreatmentNCT05377684 · lead sponsor · 2022-06-09

COMPLETED

Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.NCT04593420 · lead sponsor · 2020-11-30

COMPLETED

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)NCT03773133 · lead sponsor · 2019-05-14

TERMINATED

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast CancerNCT03697551 · lead sponsor · 2018-10-22

TERMINATED

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung CancerNCT03088813 · lead sponsor · 2018-04-25

COMPLETED

Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist TherapyNCT03516110 · lead sponsor · 2018-03-09

COMPLETED

To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer PatientsNCT03017313 · lead sponsor · 2017-07-13

COMPLETED

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursNCT02683941 · lead sponsor · 2017-03-06

TERMINATED

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2NCT02660359 · lead sponsor · 2016-07-08

TERMINATED

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1NCT02660138 · lead sponsor · 2016-03-01

TERMINATED

Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.NCT02630641 · lead sponsor · 2015-10-01

COMPLETED

Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) AnaloguesNCT02542501 · lead sponsor · 2015-07-01

COMPLETED

Quality of Life of Patients With Locally Advanced and Metastatic Prostate CancerNCT02853409 · lead sponsor · 2014-01-01

COMPLETED

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate CancerNCT02057666 · lead sponsor · 2014-01-01

TERMINATED

Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate CancerNCT02238366 · lead sponsor · 2013-11-01

COMPLETED

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based ChemotherapyNCT01732549 · lead sponsor · 2013-01-01

TERMINATED

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate CancerNCT01715129 · lead sponsor · 2013-01-01

COMPLETED

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.NCT01753297 · lead sponsor · 2012-12-11

COMPLETED

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentNCT01770353 · lead sponsor · 2012-11-01

COMPLETED

GP Extended Action TriptorelinNCT01673984 · lead sponsor · 2012-08-01

TERMINATED

Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant StateNCT01560858 · lead sponsor · 2012-04-01

COMPLETED

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.NCT01562522 · lead sponsor · 2012-03-01

TERMINATED

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate CancerNCT01374087 · lead sponsor · 2011-11-01

TERMINATED

A Long-term Observational Study Cohort in Patients With Advanced Prostate CancerNCT01383863 · lead sponsor · 2011-10-01

COMPLETED

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer PatientsNCT01313273 · lead sponsor · 2011-06-01

TERMINATED

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple SclerosisNCT01357980 · lead sponsor · 2011-05-01

COMPLETED

Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast CancerNCT01230970 · lead sponsor · 2011-05-01

TERMINATED

Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mgNCT01257425 · lead sponsor · 2010-12-01

COMPLETED

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate CancerNCT01020448 · lead sponsor · 2009-11-01

COMPLETED

BN83495 in Prostate CancerNCT00790374 · lead sponsor · 2009-01-01

COMPLETED

Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive FunctionsNCT00814346 · lead sponsor · 2008-10-01

COMPLETED

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and TreatmentNCT00489255 · lead sponsor · 2007-05-01

COMPLETED

BN83495 Phase I in Post-menopausal WomenNCT01840488 · lead sponsor · 2007-04-01

COMPLETED

Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)NCT00444639 · lead sponsor · 2007-02-01

TERMINATED

Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate CancerNCT00415246 · lead sponsor · 2006-11-01

TERMINATED

Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's DiseaseNCT00500500 · lead sponsor · 2005-07-01

TERMINATED

Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAqNCT00234533 · lead sponsor · 2004-06-01

COMPLETED

Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)NCT00080015 · lead sponsor · 2004-03-12

COMPLETED

Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple SclerosisNCT00276341 · lead sponsor · 2003-08-26

COMPLETED

A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory ComplaintsNCT00276510 · lead sponsor · 2002-02-01

COMPLETED

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in AlgeriaNCT07484971 · collaborator · 2025-07-21

RECRUITING

Long-term Better Than Short-term ADT With Salvage RTNCT04242017 · collaborator · 2020-07-07

RECRUITING

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)NCT05255666 · collaborator · 2023-07-31

WITHDRAWN

Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer TreatmentNCT06217770 · collaborator · 2023-04-01

COMPLETED

Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRTNCT04624828 · collaborator · 2020-10-19

ACTIVE_NOT_RECRUITING

Phase II Study With Cabozantinib in Patients With RET Positive NSCLCNCT04131543 · collaborator · 2019-08-07

UNKNOWN

CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITYNCT04673240 · collaborator · 2019-03-29

UNKNOWN

" Treating MS Patients With Lower Extremity Spasticity Using Dysport"NCT03585569 · collaborator · 2018-05-01

UNKNOWN

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerNCT01957436 · collaborator · 2013-11-13

ACTIVE_NOT_RECRUITING

A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer GrowthNCT01662726 · collaborator · 2012-08-01

TERMINATED

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate CancerNCT01214291 · collaborator · 2011-03-01

WITHDRAWN

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate CancerNCT00667069 · collaborator · 2008-04-07

COMPLETED

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast CancerNCT00630695 · collaborator · 2008-03-01

COMPLETED

Sponsor roles

lead sponsor43

collaborator13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.